Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO a

[News]

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

More... (http://www.news-medical.net/news/20140604/Provectuse28099-PV-10-data-for-intralesional-treatment-of-solid-tumors-presented-at-ASCO-annual-meeting.aspx)